Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Limited has appointed Mr. Chirag Shukla as Company Secretary & Compliance Officer (Key Managerial Personnel), effective August 20, 2026, according to a regulatory filing. Mr. Shukla, a qualified Company Secretary and Law Graduate with over 19 years of experience, previously worked at Deepak Phenolics Limited, Schaeffler India Limited, Alembic Limited and Bhavnagar Energy Company Limited.

Alembic Pharmaceuticals Ltd share price gained 1.14% to Rs 806.1 after the company's net profit dropped 14.47% to Rs 172.36 crore, while revenue from operations edged up 16.35% to Rs 2149.77 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.75 lakh crore, rising 6.24%. It has inched up 1.51% over last one week and moving up by 11.59% in last one month while the market capitalization of Alembic Pharmaceuticals Ltd has eased by 1.49% and 2.60% in the same period respectively. Profit before tax (PBT) of Alembic Pharmaceuticals Ltd stood at Rs 221.86 crore in Q2 FY26, jumping 16.70% year-on-year, and surging by 87.03% quarter-on-quarter. EBITDA came in at Rs 317 crore, expanding by 15.31% YoY and rallying 56.57% sequentially. Total expenses rose by 12.13% to Rs 1915.62 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 517.3 crore, witnessing a sharp rise of 27.97% YoY, while employee benefits expense was at Rs 473.94 crore, rising by 7.98% YoY. For the TTM ended FY26, revenue from operations grew 10.08% to Rs 7344.9 crore, while net profit improved by 15.26% to Rs 670.83 crore, compared to previous TTM. EBITDA soared by 100466% to Rs 1064.05 crore, and PBT softened 1.87% to Rs 693.95 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 782.73 crore in FY26, as against Rs 87.97 crore in FY25. Alembic Pharmaceuticals Ltd tumbled by 16.66% in last one year, underperforming the benchmark BSE Sensex which has eased by 2.94% during the same period.

Alembic Pharmaceuticals Limited reported a 26% increase in revenue from operations to Rs 2150 crore for the first quarter ended June 30, 2026, according to a revised press release. The company’s profit after tax rose 12% year-on-year to Rs 173 crore, with EBITDA pre R&D increasing to Rs 523 crore, representing a 24% margin, while the India Branded Business delivered 7% year-on-year growth, reaching Rs 642 crore in revenue. The US Formulation business grew by 49% to Rs 778 crore, with seven product launches in the US market during the quarter, and the API business increased by 33% to Rs 346 crore.

Alembic Pharmaceuticals Limited reported consolidated revenue from operations increased by 26% to Rs 2150 crore for the quarter ended June 30, 2026, with a profit after tax of Rs 173 crore, up 12% year-on-year, according to a press release. The company’s US formulation business grew by 49% to Rs 778 crore, driven by seven new product launches, while its India branded business increased 7% to Rs 642 crore, and the API business grew by 33% to Rs 346 crore.

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Prucalopride Tablets, 1 mg and 2 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA Inc. Prucalopride tablets are serotonin-4 receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.  Prucalopride Tablets, 1 mg and 2 mg, have an estimated market size of US$ 100 million for twelve months ending March 2026 according to IQVIA.

Alembic Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 4 August 2026.

The approved abbreviated new drug application (ANDA) is therapeutically equivalent to the reference listed drug (RLD), Lynparza Tablets, 100 mg and 150 mg, marketed by AstraZeneca Pharmaceuticals LP, for the indications specified in the approved labelling. Under the partnership arrangement, NATCO Pharma will manufacture the Olaparib tablets, while Alembic Pharmaceuticals will distribute the product in the United States. The company said the Paragraph IV (Para IV) patent litigation related to the product is ongoing. According to IQVIA, Olaparib Tablets, 100 mg and 150 mg, had an estimated U.S. market size of approximately $1.4 billion for the 12 months ended March 2026. With this approval, Alembic Pharmaceuticals now has a cumulative total of 244 ANDA approvals from the USFDA, comprising 224 final approvals and 20 tentative approvals. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. The company's consolidated net profit jumped 29.19% to Rs 202.70 crore in Q4 FY26, compared to Rs 156.89 crore posted in Q4 FY25. Revenue from operations grew 4.41% year on year (YoY) to Rs 1,847.72 crore in the quarter ended 31 March 2026. Powered by Capital Market - Live

Alembic Pharmaceuticals announced that the 16th Annual General Meeting(AGM) of the company will be held on 5 August 2026.

The approved ANDA is therapeutically equivalent to Aczone Gel, 5%, of Almirall, LLC, and is indicated for the topical treatment of acne vulgaris. With this approval, Alembic Pharmaceuticals now has a cumulative total of 244 ANDA approvals from the USFDA, comprising 224 final approvals and 20 tentative approvals. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. The company's consolidated net profit jumped 29.19% to Rs 202.70 crore in Q4 FY26, compared to Rs 156.89 crore posted in Q4 FY25. Revenue from operations grew 4.41% year on year (YoY) to Rs 1,847.72 crore in the quarter ended 31 March 2026.Powered by Capital Market - Live

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Dapsone Gel, 5%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Aczone Gel, 5%, of Almirall, LLC. Dapsone Gel is indicated for the topical treatment of acne vulgaris. Refer label for a detailed indication. Alembic has a cumulative total of 244 ANDA approvals (224 final approvals and 20 tentative approvals) from USFDA.